MENU
PHAT
AS OF
Feb 4, 03:11 PM (EDT)
Price
$12.83
Change
-$0.98 (-7.10%)
Capitalization
1.08B
27 days until earnings call
Intraday BUY SELL Signals
+Compare
PHAT
Stock ticker: NASDAQ
AS OF
Feb 4, 03:11 PM (EDT)
Price
$12.83
Change
-$0.98 (-7.10%)
Capitalization
1.08B

PHAT Phathom Pharmaceuticals Forecast, Technical & Fundamental Analysis

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company... Show more

PHAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PHAT with price predictions
Feb 03, 2026

PHAT sees its Stochastic Oscillator recovers from oversold territory

On February 02, 2026, the Stochastic Oscillator for PHAT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 61 instances where the indicator left the oversold zone. In of the 61 cases the stock moved higher in the following days. This puts the odds of a move higher at over .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PHAT advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PHAT moved out of overbought territory on December 29, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on January 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PHAT as a result. In of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PHAT turned negative on January 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

PHAT moved below its 50-day moving average on January 14, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for PHAT crossed bearishly below the 50-day moving average on January 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PHAT entered a downward trend on January 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PHAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (27.519). P/E Ratio (0.000) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.893). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (6.775) is also within normal values, averaging (331.843).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
PHAT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PHAT is expected to report earnings to rise 178.67% to -41 cents per share on March 03

Phathom Pharmaceuticals PHAT Stock Earnings Reports
Q4'25
Est.
$-0.42
Q3'25
Beat
by $0.32
Q2'25
Beat
by $0.12
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.42
The last earnings report on October 30 showed earnings per share of -15 cents, beating the estimate of -46 cents. With 96.87K shares outstanding, the current market capitalization sits at 1.08B.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
100 Campus Drive
Phone
+1 877 742-8466
Employees
452
Web
https://www.phathompharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NRFAX13.130.09
+0.69%
Natixis AEW Global Focused Real Estate A
GVCAX11.910.02
+0.17%
Gabelli Value 25 AAA
NOMIX21.84N/A
N/A
Northern Mid Cap Index
MXETX13.49N/A
N/A
Empower Core Strategies US Eq Inv
UBVUX81.48-0.06
-0.07%
Undiscovered Managers Behavioral Val R4

PHAT and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with QCLS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then QCLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
N/A
QCLS - PHAT
39%
Loosely correlated
-1.76%
URGN - PHAT
36%
Loosely correlated
+1.52%
RGNX - PHAT
36%
Loosely correlated
+0.74%
ATRA - PHAT
36%
Loosely correlated
N/A
ALGS - PHAT
33%
Loosely correlated
-5.41%
More